Afatinib in EGFR TKI-naive patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial

被引：0
|
作者：
Passaro, A. [1 ]
Laktionov, K. K. [2 ]
Poltoratskiy, A. [3 ]
Egorova, I. [4 ]
Hochmair, M. [5 ]
Migliorino, M. R. [6 ]
Metro, G. [7 ]
Gottfried, M. [8 ]
Tsoi, D. [9 ]
Ostoros, G. [10 ]
Rizzato, S. [11 ]
Mukhametshina, G. Z. [12 ]
Schumacher, M. [13 ]
Novello, S. [14 ]
Dziadziuszko, R. [15 ]
Tang, W. [16 ]
Clementi, L. [17 ]
Cseh, A. [18 ]
Kowalski, D. [19 ]
De Marinis, F. [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
[2] Russian Acad Med Sci, Moscow, Russia
[3] Petrov Res Inst Oncol, St Petersburg, Russia
[4] Clin Oncol Dispensary, St Petersburg, Russia
[5] Otto Wagner Hosp, Vienna, Austria
[6] San Camillo Forlanini Hosp, Rome, Italy
[7] Santa Maria Misericordia Hosp, Perugia, Italy
[8] Tel Aviv Univ, Tel Aviv, Israel
[9] St John God Murdoch Hosp, Murdoch, WA, Australia
[10] Natl Koranyi Inst Pulmonol, Budapest, Hungary
[11] Azienda Sanit Univ Integrata, Udine, Italy
[12] Minist Hlth Republ Tatarstan, Kazan, Russia
[13] Ordensklinikum Elisabethinen, Linz, Austria
[14] Univ Turin, Turin, Italy
[15] Med Univ Gdansk, Gdansk, Poland
[16] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[17] Boehringer Ingelheim Italia SpA, Milan, Italy
[18] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
[19] Oncol Ctr & Inst, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
115O
引用
收藏
页数：2
相关论文
共 50 条
  • [41] EFFICACY OF AFATINIB VS. CHEMOTHERAPY IN TREATMENT-NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBOURING ACTIVATING EGFR MUTATIONS WITH OR WITHOUT METASTATIC BRAIN DISEASE
    Schuler, Martin
    Yang, James C.
    Sequist, Lecia V.
    Hirsh, Vera
    O'Byrne, Kenneth
    Yamamoto, Nobuyuki
    Massey, Daniel
    Shahidi, Mehdi
    Zazulina, Victoria
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S299 - S300
  • [42] An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
    Park, Keunchil
    Kim, Jin-Soo
    Kim, Joo-Hang
    Kim, Young-Chul
    Kim, Hoon-Gu
    Cho, Eun Kyung
    Jin, Jong-Youl
    Kim, Miyoung
    Marten, Angela
    Kang, Jin-Hyoung
    BMC CANCER, 2021, 21 (01)
  • [43] Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results
    Reckamp, K. L.
    Gilman, P.
    Halmos, B.
    Jahanzeb, M.
    McCann, J.
    Paripati, H.
    Seneviratne, L. C.
    Wallace, J. A.
    Rueter, B.
    Esler, A.
    Dowling, E.
    Koczywas, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 527 - 527
  • [44] Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial).
    Inal, Cengiz
    Piperdi, Bilal
    Keller, Steven M.
    Halmos, Balazs
    Stoopler, Mark
    Limaye, Sewanti Atul
    Levy, Benjamin Philip
    Schneider, Bryan J.
    Kim, Mimi
    Sides, Jessica
    Perez-Soler, Roman
    Cheng, Haiying
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study
    Helland, A.
    Andersen, K. K.
    Myklebust, T. A.
    Johannesen, T. B.
    Hallerback, T.
    Enerly, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S889 - S889
  • [46] A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naive Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Crawford, J.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S281 - S282
  • [47] A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung
    Padda, S.
    Reckamp, K.
    Koczywas, M.
    Neal, J.
    Kawashima, J.
    Kong, S.
    Xin, Y.
    Huang, D.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2142 - S2143
  • [48] A Historical Comparison of Patients with Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan
    Kawamura, T.
    Murakami, H.
    Kobayashi, H.
    Nakashima, K.
    Omori, S.
    Wakuda, K.
    Ono, A.
    Kenmotsu, H.
    Naito, T.
    Endo, M.
    Takahashi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S888 - S888
  • [49] Survival analysis of advanced NSCLC patients harboring EGFR mutations with zoledronate or denosumab
    Miwa, Maki
    Okuma, Yusuke
    Kashima, Jumpei
    Hosomi, Yukio
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [50] EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
    Helland, Aslaug
    Andersen, Klaus Kaae
    Myklebust, Tor age
    Johannesen, Tom Borge
    Aaroe, Jorgen
    Enerly, Espen
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
12345